Abstract ▼

< Purpose >
▶ Generating humanized immune mice with a fully competent human immune system by transplanting of human cord blood-derived CD34+ hematopoietic stem cells.
▶ Establishing a research platform for cell therapy agents using humanized mouse disease models.

< Background >
▶ A p

< Purpose >
▶ Generating humanized immune mice with a fully competent human immune system by transplanting of human cord blood-derived CD34+ hematopoietic stem cells.
▶ Establishing a research platform for cell therapy agents using humanized mouse disease models.

< Background >
▶ A preclinical model with a human immune system is needed to evaluate cell therapeutics that are in the spotlight as next-generation treatments for various immune diseases.
▶ Development of disease models are required to understand the immunological mechanism of cell therapeutics to overcome various immune diseases. So we plan to make models using human hematopoietic stem cells that are transplanted humanized mice

< Contents/Results >
▶ Separation of hematopoietic stem cells by securing cord blood and analysis of HLA type of hematopoietic stem cells
▶ Construction of humanized mice
- 1^st year: Transplanting hematopoietic stem cells into immunodeficient mice (NBSGW) or cytokine-expressing immunodeficient mice (NSG-SGM3) to make humanized mice with human immune system (N=140) and completion of immune profiling
- 2^nd year: Based on cytokine-expressing immunodeficient mice (NSG-SGM3), construction of 100 humanized mice matching HLA type with cell therapeutics and 100 humanized mice mis-matching HLA type with cell therapeutics and completion of immune profiling
▶ Construction of humanized mice-based on disease model
- Construction of wounded healing and pulmonary fibrosis disease model
- In the second year, we selected a specific cancer disease and performed in-vitro efficacy test. In addition, we scheduled in-vivo efficacy evaluation used humanized mice.

< Expected Contribution >
▶ Development of humanized mice for transplantation of differentiated cells-derived from homozygous HLA type iPSC will be contributed the application of cell therapeutic agents that are developed by the National Stem Cell Bank for incurable disease.
▶ We will prepare for future domestic demands for therapeutics by clinical application of GMP grade HLA type iPSC .

(source : Summary 5p)

목차 Contents

• 표지 ... 1
• 연구결과점검보고서 ... 2
• 목차 ... 3
• 요약문 ... 4
• Summary ... 5
• 학술연구개발용역과제 연구결과 ... 6
• 제1장 최종 목표 ... 6
• 제2장 국내외 기술 현황 ... 13
• 제3장 최종 연구 내용 및 방법 ... 15
• 제4장 최종 연구 결과 ... 20
• 제5장 연구결과 고찰 및 결론 ... 106
• 제6장 연구성과 및 활용계획 ... 108
• 제7장 연구용역과제 진행과정에서 수집한 해외과학기술정보 ... 110
• 제8장 기타 중요변경사항 ... 111
• 제9장 연구비 사용 내역(당해년도) 및 연구원 분담표 ... 112
• 제10장 참고문헌 ... 114
• 제11장 첨부서류 ... 115
• 끝페이지 ... 115